arrow
E

Emilia Antonucci

AUSL di Bologna
H指数:34
被引数:5,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality

癌症合并心房颤动患者中直接口服抗凝剂与华法林的质量比较

Cancer
IF5.1
2026-08-110
OAAI
Descriptive analysis of the Nationwide START2 antiphospholipid registry: Clinical and laboratory characteristics of patients with persistently positive antiphospholipid antibodies

全国性START2抗磷脂抗体登记研究的描述性分析:持续阳性抗磷脂抗体患者的临床和实验室特征

2026-08-010
PRE
Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials

阿司匹林在冠状动脉疾病二级预防中的年龄相关疗效:START-ANTIPLATELET注册研究和随机试验的荟萃分析

2026-05-200
PRE
Effectiveness of direct oral anticoagulants for all-cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

直接口服抗凝剂对房颤超重和肥胖患者全因死亡率及心血管事件的有效性:来自全国性START注册研究的见解

2025-11-130
OAAI
Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

中度/重度慢性肾脏疾病合并心房颤动患者直接口服抗凝剂的实世界应用:一项来自START注册研究的倾向性评分匹配分析

2025-11-030
OAAI
Frailty elements, direct oral anticoagulants and mortality risk in atrial fibrillation patients aged ≥ 80 or ≥ 90 years from the nationwide Italian START registry: a propensity score matching analysis

脆弱性因素、直接口服抗凝剂以及≥80岁或≥90岁房颤患者的死亡风险:来自意大利全国性START注册研究的倾向性评分匹配分析

2025-10-220
OA
Low-dose of direct oral anticoagulants for secondary prevention in patients at high risk for recurrence due to history of recurrent venous thromboembolic events or to severe thrombophilia: a retrospective analysis of the Italian START2 Registry

对于有复发性静脉血栓栓塞事件史或严重血栓ophilia史的高复发风险患者,采用低剂量直接口服抗凝剂进行二级预防:一项意大利START2登记研究的回顾性分析

2025-08-110
PRE
Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry

接种新冠疫苗后发生的血栓事件:来自意大利血栓与止血学会登记系统的报告

2025-07-300
OAAI
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome

Semaglutide在患有急性冠状动脉综合征的超重和肥胖患者中的资格和实际意义

2025-03-010
OAAI
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
2024-09-165
OAAI
ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET Registry

ACEF与PARIS评分在预测急性冠状动脉综合征患者心血管事件中的比较:START ANTIPLATELET注册研究的见解

2024-08-270
PRE